InvestSMART

Chimeric Therapeutics Limited (ASX:CHM)

ALERT: Price-sensitive ASX Announcement for CHM
Current share price for CHM : $0.065 -0.145 (-69.05%)+
Announcement
Release
29 Apr 2026 3:41PM
Price at Release
$0.210
Full Release
download
Summary
Chimeric Therapeutics Limited reported significant advancements in its clinical programs and financial activities for the quarter ending 31 March 2026. The CHM CDH17 trial has progressed to Dose Level 3 with promising results, including stable disease in colorectal cancer patients and no safety issues observed. The CHM CORE-NK Phase 1b trial reported a 60% CR/CRi rate. The company streamlined its portfolio by returning the CHM CLTX asset to City of Hope. Financially, Chimeric had a net cash outflow from operating activities of $3.42 million, primarily used for staff and R&D expenses, and secured $2.68 million in net financing inflows. The company also raised $4.4 million in a recent placement and received a $1.8 million advance on its FY26 R&D tax incentive.
Key Points
  • CHM CDH17 trial advanced to Dose Level 3 with no safety concerns.
  • Stable disease observed in colorectal cancer patients for up to 13 months.
  • CHM CORE-NK trial achieved a 60% CR/CRi rate.
  • Portfolio streamlined by returning CHM CLTX asset to City of Hope.
  • Net cash outflow of $3.42 million in operating activities.
  • Secured $2.68 million in net financing inflows.
  • Raised $4.4 million in recent placement and received $1.8 million R&D tax incentive advance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.